Evidence map›Paper›PMID 36882409›Full record

ArticleBlood cancer journal2023

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.

Philippe Moreau, Ajai Chari, Albert Oriol, Joaquin Martinez-Lopez, Mathias Haenel, Cyrille Touzeau, Sikander Ailawadhi, Britta Besemer, Javier de la Rubia Comos, Cristina Encinas and 18 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Philippe MoreauHematology, University Hospital Hôtel-Dieu, Nantes, France. philippe.moreau@chu-nantes.fr.ORCID 0000-0003-1780-8746
Ajai ChariIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Albert OriolInstitut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain.ORCID 0000-0001-6804-2221
Joaquin Martinez-LopezHospital 12 de Octubre, H12O-CNIO, Haematological Malignancies Clinical Research Unit, Universidad Complutense, CIBERONC, Madrid, Spain.
Mathias HaenelKlinikum Chemnitz, Chemnitz, Germany.
Cyrille TouzeauHematology, University Hospital Hôtel-Dieu, Nantes, France.ORCID 0000-0003-0275-2575
Sikander AilawadhiMayo Clinic Florida, Jacksonville, FL, USA.ORCID 0000-0002-8377-8111
Britta BesemerUniversitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II, Tübingen, Germany.
Javier de la Rubia ComosHospital La Fe, School of Medicine and Dentistry, Catholic University of Valencia, Valencia, Spain.ORCID 0000-0002-8354-768X
Cristina EncinasHospital General Universitario Gregorio Marañón (HGUGM), IiSGM, Madrid, Spain.ORCID 0000-0002-9001-9754
Maria-Victoria MateosUniversity Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain.ORCID 0000-0003-2390-1218
Hans SalwenderAsklepios Tumorzentrum Hamburg, AK Altona and AK St. Georg, Hamburg, Germany.ORCID 0000-0001-7803-0814
Paula Rodriguez-OteroClínica Universidad de Navarra, Pamplona, Spain.ORCID 0000-0001-5236-7785
Cyrille HulinDepartment of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France.ORCID 0000-0002-3749-5161
Lionel KarlinDepartment of Hematology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
Anna Sureda BalariHematology Department, Institut Català d'Oncologia - Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain.
Joan BargayHospital Universitari Son Llàtzer, IdISBa, Palma de Mallorca, Illes Balears, Spain.
Lotfi BenboubkerService d'Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire (CHRU), Tours, France.
Laura RosiñolHospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain.ORCID 0000-0002-2534-9239
Stefano TarantoloNebraska Cancer Specialists, Omaha, NE, USA.
Howard TerebeloProvidence Cancer Center, Southfield, MI, USA.
Shiyi YangJanssen Research & Development, LLC, Spring House, PA, USA.
Jianping WangJanssen Research & Development, LLC, Spring House, PA, USA.
Ivo NnaneJanssen Research & Development, LLC, Spring House, PA, USA.
Ming QiJanssen Research & Development, LLC, Spring House, PA, USA.
Michele KoshJanssen Research & Development, LLC, Spring House, PA, USA.
Maria DelioukinaJanssen Research & Development, LLC, Spring House, PA, USA.
Hartmut GoldschmidtGMMG-Study Group at University Hospital Heidelberg, Internal Medicine V, Heidelberg, Germany.ORCID 0000-0003-0961-0035

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Keith L. Knutson · 1985 to 2026
$151.3M
NCI NIH HHS P30 CA015083
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multiple MyelomaNeoplasms, Plasma CellAntibodies, MonoclonalDexamethasoneHumansOligopeptidesAntibodies, MonoclonalcarfilzomibdaratumumabDexamethasoneOligopeptides

Identifiers

PMID36882409
PMCPMC9989580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.